NCT01750359

Brief Summary

Antidepressants generally do not lead to an immediate relief of symptoms. Most people will not see a significant improvement for at least 4 weeks. Studies have generally shown that the full benefits of antidepressant therapy may take as long as 8 to 12 weeks. However, this timeline is variable among individuals.Curcumin is one of the main curcuminoids isolated from this perennial herb. It possesses a variety of pharmacological activities, including anti-inflammatory, antiproliferative, antioxidant, and neuroprotective effects. Curcumin has been found to possess antidepressant action in various animal models of depression. Chronic administration of curcumin has been reported to exert antidepressant-like action in olfactory bulbectomy model of depression in rats. Although the mechanism of the antidepressant effect of curcumin is not fully understood, it is hypothesized that it acts through inhibiting the monoamine oxidase enzyme and modulating the release of serotonin and dopamine.In randomized, double-blind, placebo-controlled study 40 patients will be randomized to receive either 500 mg/day of curcumin or placebo together with antidepressants for 6 weeks.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Aug 2010

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2010

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2011

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2011

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

July 25, 2012

Completed
5 months until next milestone

First Posted

Study publicly available on registry

December 17, 2012

Completed
Last Updated

February 7, 2013

Status Verified

December 1, 2012

Enrollment Period

9 months

First QC Date

July 25, 2012

Last Update Submit

February 6, 2013

Conditions

Keywords

antioxidantscurcumindepression

Outcome Measures

Primary Outcomes (2)

  • Hamilton Depression Rating Scale

    Change in the scores from baseline at six weeks

  • Montgomery-Asberg Depression Rating Scale

    Change in the scores from baseline at six weeks

Secondary Outcomes (1)

  • Clinical Global Impression

    Change in the scores from baseline at six weeks

Study Arms (2)

curcumin

ACTIVE COMPARATOR
Drug: curcumin

placebo

PLACEBO COMPARATOR
Drug: curcumin

Interventions

500 mg/day for 6 week

curcuminplacebo

Eligibility Criteria

Age20 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females in age 20-60 years
  • Major depressive episode according to DSM-IV
  • Clinical Global Impression Severity Scale scores more than 4
  • Hamilton Depression Rating Scale scores more than 21
  • Montgomery and Asberg Depression Rating Scale scores more than 22
  • Ability and willingness to sign informed consent

You may not qualify if:

  • Evidence of organic brain damage
  • Mental retardation
  • Alcohol or drug abuse
  • An unstable medical condition
  • Any significant medical or neurological illness
  • Patients with a known hypersensitivity to curcumin or other components of the product
  • Pregnant women or women who intend to become pregnant
  • Receiving any antidepressant and mood-stabilizers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tirat Carmel Mental Health Center

Tirat Carmel, 84170, Israel

Location

MeSH Terms

Conditions

Depressive Disorder, MajorDepression

Interventions

Curcumin

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental DisordersBehavioral SymptomsBehavior

Intervention Hierarchy (Ancestors)

DiarylheptanoidsHeptanesAlkanesHydrocarbons, AcyclicHydrocarbonsOrganic ChemicalsCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, Cyclic

Study Officials

  • Joseph Bergman, MD

    Tirat Carmel

    PRINCIPAL INVESTIGATOR
  • Vladimir Lerner, MD, PhD

    Beersheva Mental Health Center

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR INVESTIGATOR
PI Title
A/Professor, Head of department

Study Record Dates

First Submitted

July 25, 2012

First Posted

December 17, 2012

Study Start

August 1, 2010

Primary Completion

May 1, 2011

Study Completion

June 1, 2011

Last Updated

February 7, 2013

Record last verified: 2012-12

Locations